NCT06782425View on ClinicalTrials.gov

Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Claudin18.2 Positive Advanced Solid Tumors
Interventions
DRUG

XKDCT225

Autologous targeted claudin18.2 chimeric antigen receptor T cell injection

Trial Locations (1)

455000

RECRUITING

AnYang Tumor Hospital, Anyang

All Listed Sponsors
lead

Shenzhen Celconta Life Science Co., Ltd.

INDUSTRY